Investment Insider: The heady days aren't over for drugs groups

Genetics, stem cells and consistent dividends can offset the problems of expiring patents

The further away an operation is from head office, the less control central management has over the operation. It is something, perhaps, that GlaxoSmithKline might be more mindful of in future.

However, the travails of the UK's biggest drugs company in China might provide investors with an opportunity to take a closer look at the group. The shares have enjoyed a decent run over the last two years, climbing from around 1,250p in 2011 to a recent high of 1,777p in May this year, and it is encouraging that they have only wavered a little following allegations of bribery against senior executives in the company's China office.

The bottom line is that GlaxoSmithKline is a generous dividend payer, and there is little to suggest this will stop in the near future. That might explain why the shares remain in demand. Profits this year are expected to rise around 3 per cent to almost £7bn, while the full-year dividend payout is expected to rise 7 per cent to 77p, which would suggest a dividend yield of 4.5 per cent based on the current share price of 1,715p.

AstraZeneca is now experiencing the same patent-expiry pains endured by GlaxoSmithKline in the last few years. Revenues fell around 20 per cent last year as key drugs lost their protection against generic rivals. That said, AstraZeneca is expected to keep shareholders sweet by at least maintaining its dividend. A forecast payout of 191p would equate to a yield of 5.8 per cent.

Much has been said about the pharmaceutical industry being in decline, and in a sense that's true as drugmakers cannot continue to dine out on the chemical drugs of yesteryear. However, as healthcare keeps evolving, so biologics and pharmaceuticals will gradually merge and the drug companies of the future will be involved in areas such as genetics, stem-cell science and a host of other medical technologies.

Among these companies, neither ReNeuron nor Xenetic Biosciences is currently profitable, but that is not unusual for fledgling firms at the cutting edge of science. ReNeuron, which is worth around £23m, specialises in developing stem-cell therapies in areas where medical needs have not been met. It has a treatment for stroke patients in clinical development.

Xenetic, which is worth around £26m, specialises in novel ways of delivering drugs and vaccines. It reckons that its pipeline has multi-billion-pound market potential.

The pharmaceutical sector is peppered with companies that believe they can be the next GlaxoSmithKline or Amgen. The trouble is, the risk-reward ratio when investing in small biotechnology firms can be quite high, given that only one in 15 drugs that enter clinical trials go on to make money. Conversely, the rewards can be huge for the drug that does make it through.

Investors, though, probably have as much chance of spotting the next GlaxoSmithKline as fledgling biotechs have of actually becoming one. If you want to improve your chances, investing a little in each company is one way to spread your risk.

Alternatively, stick to the big drug groups. Many have collaborated with the small biotechs, so they should at least have their finger on the pulse.

David Kuo is director of fool.co.uk

Independent Partners; Do you need financial advice on your investments, pension or insurance? Book a free consultation with an independent Financial Adviser at VouchedFor.co.uk

Finacial products from our partners
Property search
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

ES Rentals

    iJobs Job Widget
    iJobs Money & Business

    Recruitment Genius: Sales Executive / Foreign Exchange Dealer - OTE £40,000+

    £16000 - £40000 per annum: Recruitment Genius: A Foreign Exchange Dealer is re...

    SThree: Experienced Recruitment Consultant

    £20000 - £40000 per annum + OTE + Incentives + Benefits: SThree: Established f...

    SThree: Trainee Recruitment Consultant

    £20000 - £25000 per annum + OTE 40/45k + INCENTIVES + BENEFITS: SThree: The su...

    Recruitment Genius: Collections Agent

    £14000 - £16000 per annum: Recruitment Genius: This company was established in...

    Day In a Page

    The long walk west: they fled war in Syria, only to get held up in Hungary – now hundreds of refugees have set off on foot for Austria

    They fled war in Syria...

    ...only to get stuck and sidetracked in Hungary
    From The Prisoner to Mad Men, elaborate title sequences are one of the keys to a great TV series

    Title sequences: From The Prisoner to Mad Men

    Elaborate title sequences are one of the keys to a great TV series. But why does the art form have such a chequered history?
    Giorgio Armani Beauty's fabric-inspired foundations: Get back to basics this autumn

    Giorgio Armani Beauty's foundations

    Sumptuous fabrics meet luscious cosmetics for this elegant look
    From stowaways to Operation Stack: Life in a transcontinental lorry cab

    Life from the inside of a trucker's cab

    From stowaways to Operation Stack, it's a challenging time to be a trucker heading to and from the Continent
    Kelis interview: The songwriter and sauce-maker on cooking for Pharrell and crying over potatoes

    Kelis interview

    The singer and sauce-maker on cooking for Pharrell
    Refugee crisis: David Cameron lowered the flag for the dead king of Saudi Arabia - will he do the same honour for little Aylan Kurdi?

    Cameron lowered the flag for the dead king of Saudi Arabia...

    But will he do the same honour for little Aylan Kurdi, asks Robert Fisk
    Our leaders lack courage in this refugee crisis. We are shamed by our European neighbours

    Our leaders lack courage in this refugee crisis. We are shamed by our European neighbours

    Humanity must be at the heart of politics, says Jeremy Corbyn
    Joe Biden's 'tease tour': Could the US Vice-President be testing the water for a presidential run?

    Joe Biden's 'tease tour'

    Could the US Vice-President be testing the water for a presidential run?
    Britain's 24-hour culture: With the 'leisured society' a distant dream we're working longer and less regular hours than ever

    Britain's 24-hour culture

    With the 'leisured society' a distant dream we're working longer and less regular hours than ever
    Diplomacy board game: Treachery is the way to win - which makes it just like the real thing

    The addictive nature of Diplomacy

    Bullying, betrayal, aggression – it may be just a board game, but the family that plays Diplomacy may never look at each other in the same way again
    Lady Chatterley's Lover: Racy underwear for fans of DH Lawrence's equally racy tome

    Fashion: Ooh, Lady Chatterley!

    Take inspiration from DH Lawrence's racy tome with equally racy underwear
    8 best children's clocks

    Tick-tock: 8 best children's clocks

    Whether you’re teaching them to tell the time or putting the finishing touches to a nursery, there’s a ticker for that
    Charlie Austin: Queens Park Rangers striker says ‘If the move is not right, I’m not going’

    Charlie Austin: ‘If the move is not right, I’m not going’

    After hitting 18 goals in the Premier League last season, the QPR striker was the great non-deal of transfer deadline day. But he says he'd preferred another shot at promotion
    Isis profits from destruction of antiquities by selling relics to dealers - and then blowing up the buildings they come from to conceal the evidence of looting

    How Isis profits from destruction of antiquities

    Robert Fisk on the terrorist group's manipulation of the market to increase the price of artefacts
    Labour leadership: Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea

    'If we lose touch we’ll end up with two decades of the Tories'

    In an exclusive interview, Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea